This announcement is a separate document:
Chimeric Therapeutics Ltd: CHM CDH17 Phase 1/2 clinical trial approved for initiation
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.